Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Imke H. Bartelink, Chris Dickhoff, Johannes M.A. Daniels, Peter M. van de Ven, Joris Veltman, Sayed M.S. Hashemi, Idris Bahce, Suresh Senan, Teodora Radonic, Juan J. Garcia-Vallejo, Tanja D. de Gruijl, Marieke L. Fransen, Famke L. Schneiders, David J. Heineman, Lilian J. Meijboom, Daniela E. Oprea-Lager
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer, 20(1):764. BioMed Central
Dickhoff, C, Senan, S, Schneiders, F L, Veltman, J, Hashemi, S, Daniels, J M A, Fransen, M, Heineman, D J, Radonic, T, van de Ven, P M, Bartelink, I H, Meijboom, L J, Garcia-Vallejo, J J, Oprea-Lager, D E, de Gruijl, T D & Bahce, I 2020, ' Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial ', BMC Cancer, vol. 20, no. 1, 764 . https://doi.org/10.1186/s12885-020-07263-9
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer, 20(1):764. BioMed Central
Dickhoff, C, Senan, S, Schneiders, F L, Veltman, J, Hashemi, S, Daniels, J M A, Fransen, M, Heineman, D J, Radonic, T, van de Ven, P M, Bartelink, I H, Meijboom, L J, Garcia-Vallejo, J J, Oprea-Lager, D E, de Gruijl, T D & Bahce, I 2020, ' Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial ', BMC Cancer, vol. 20, no. 1, 764 . https://doi.org/10.1186/s12885-020-07263-9
BackgroundThe likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens
Autor:
Paul A. M. van Leeuwen, Rik J. Scheper, Mari F.C.M. van den Hout, Bas D. Koster, Tanja D. de Gruijl, Rieneke van de Ven, Berbel J.R. Sluijter, Petrousjka van den Tol, Alfons J.M. van den Eertwegh, Barbara G. Molenkamp
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Melanoma cutis is virtually incurable when it has metastasized to distant organs. Unfortunately, there is no safe and effective adjuvant treatment available for early stage patients that may prevent the development of metastasis. Si